Posts

Showing posts with the label MorningMeetingRecaps

Jim Cramer's Investing Club meeting Thursday: Meta, Eli Lilly, Estee Lauder

Image
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Thursday's key moments. Don't sell Meta Look past Eli Lilly's tough quarter Chance to buy Estee Lauder 1. Don't sell Meta Shares of Meta Platforms (META) soared more than 25% Thursday morning, to $192.50 apiece, after the tech giant reported a fourth-quarter earnings beat Wednesday evening and announced a $40 billion stock buyback plan. The quarter was exactly what we had been waiting for, as the company demonstrated it's serious about controlling costs. CEO Mark Zuckerberg on Wednesday called 2023 "the year of efficiency," while lowering Meta's 2023 expenses outlook by $5 billion. We're holding onto our shares of Meta and expect the stock to move even higher, if Zuckerberg follows through on his promise to rein in spending. 2. Look past Eli Lilly's tough quarter Eli Lilly (LLY) stock was down

Here's why we're bullish on this mega-cap stock and cautious on this health name

Image
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. Earnings and inflation Watch J & J Strong outlook for Meta 1. Earnings and inflation U.S. stocks edged higher Monday, with the Dow jumping over 150 points, rallying after a tough week for the major Wall Street gauges. We're looking ahead to second-quarter earnings Friday, kicking off with financials like Club holding Wells Fargo (WFC). Consumer price index (CPI) data will be released Wednesday, which will give the market a better read on the inflation situation. Overall, there's a lot of uncertainty for the U.S. economy as inflation stays high and the Federal Reserve mulls over further monetary tightening in order to cool a resilient labor market. 2. Watch J & J We're watching for closing arguments in a talc lawsuit against Johnson & Johnson (JNJ) brought by a 24-year-old in California